Odia researcher leads team conducting study on COVID-19 drug
Bhubaneswar: Though COVID-19 has brought entire world to a standstill due to unavailability of vaccine and particular treatment, an ongoing study led by an Odia researcher on a drug for treatment of Covid patients has given hope to billions.
A team comprising of three researchers including an Odia youth Aditya Kumar Padhi is conducting a study in Japan on an existing drug ‘Umifenovir’ to find whether it can be effective for treating COVID-19 patients with mild symptoms.
The 32-year-old Padhi is a postdoctoral research fellow at RIKEN Yokohama Campus, Japan.
He is leading the research study to find ‘Umifenovir’, the potential anti-influenza drug, which has been recommended and used by the countries — China and Russia to curb COVID fatality rate, can cure the COVID-19 infected patients.
Padhi hails from Rayagada district. His father is a retired government employee. After successfully completing his matriculation from the GCD High School in 2003 and intermediate course from Rayagada Autonomous College in 2005, he studied BTech in biotechnology at Biju Patnaik University of Technology (BPUT), Rourkela. He completed his PhD in biological sciences from IIT Delhi in 2016.